Aakaar Medical Technologies Q2FY26 Concall Decoded: Beauty Meets Bureaucracy — and EBITDA Takes a Facial
1. Opening Hook
Aakaar Medical Technologies just wrapped up its first earnings call as a listed company — and like any good cosmetic treatment, it was part glamour, part pain. While the aesthetic market glows with promise, Aakaar’s H1 results looked like a pre-makeup selfie: honest, a little blotchy, but full of potential. Management insists the “tightening of credit controls” is the skincare routine needed before the big glow-up. Stick around — this call had Botox, balance sheets, and bold claims that’ll make even your dermatologist raise an eyebrow.
Receivable Days ~130 → Target <100: The new skincare regime: cut credit, improve complexion.
3. Management’s Key Commentary
“We’ve evolved from a distributor to an asset-light innovation-driven company.” (Translation: From middleman to middle-tier manufacturer — but with better lighting. 😏)
“We’re the only aesthetic company in India with such a broad portfolio.” (Aesthetics meets monopoly — because who else sells Botox and psoriasis cream in one catalogue?)
“This quarter’s dip was due to seasonality and stricter credit controls.” (Basically, we ghosted our slow-paying customers.)
“We’ll end the year with better cash flows and positive PAT.” (Classic management contouring — highlight the future, conceal the present.)
“We train over 1,000 doctors annually across India.” (Their products teach dermatologists how to inject optimism, too. 💉)
“Our goal is to reduce receivable days to 100.” (The only ‘tightening’ this company is serious about isn’t skin tightening — it’s working capital tightening.)
“We want to be India’s No.1 aesthetic company, ₹1,000 crore in revenue.” (Ambition level: Elon Musk at a laser clinic.)
